Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study ; volume:19 ; number:1 ; day:25 ; month:3 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (25.3.2019), 1-10, 12.2019

Urheber
Parsons, Janet A.
Greenspan, Nicole R.
Baker, Natalie A.
McKillop, Chris
Hicks, Lisa K.
Chan, Olivia
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12885-019-5467-x
URN
urn:nbn:de:101:1-2019041621335689581949
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:58 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Parsons, Janet A.
  • Greenspan, Nicole R.
  • Baker, Natalie A.
  • McKillop, Chris
  • Hicks, Lisa K.
  • Chan, Olivia
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Management of Relapsed and Refractory Multiple Myeloma: Recent advances

Management of Relapsed and Refractory Multiple Myeloma: Recent advances

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Verbundene Objekte